Recently, the IND application for a Class 1 new drug— "Respiratory Syncytial Virus mRNA Vaccine" —jointly submitted by Ab&B Bio-Tech Co. Ltd. JS (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.

Of particular note is that this vaccine has also obtained clinical trial approval from the U.S. FDA, demonstrating its global development potential. This marks another product of the company to receive dual regulatory approvals for clinical trials in both China and the United States, fully showcasing its outstanding R&D capabilities and international strategic footprint, while further highlighting the company's steadfast commitment and confidence in implementing its overseas expansion strategy.

Following the approval of its respiratory syncytial virus mRNA vaccine clinical trial application by the U.S. Food and Drug Administration (FDA), the company has now received further approval from the Center for Drug Evaluation of the China National Medical Products Administration. This achievement not only marks another milestone for the company's mRNA technology platform but also demonstrates its growing maturity, laying a solid foundation for Ab&B Bio's future in-depth expansion and product iteration in the mRNA technology field.

The sustained output of innovative achievements is attributed to the company's forward-looking deployment of the mRNA technology platform. The core advantages of this platform lie in its agile R&D capabilities and scalable production potential. As a "digital" platform, it enables rapid design and synthesis upon obtaining the target sequence, facilitating swift iteration. In terms of safety, mRNA does not enter the cell nucleus, eliminating the risk of genomic integration. Regarding efficacy, through sequence optimization and advanced delivery systems, it simultaneously activates robust humoral and cellular immunity.

Currently, the company has accumulated substantial technical expertise in developing mRNA vaccines targeting single pathogens in the field of infectious disease vaccines. In addition to its existing products—the RSV mRNA vaccine and the monkeypox virus mRNA vaccine—the company is rapidly expanding its efforts toward developing combination mRNA vaccines targeting multiple pathogens. It is also applying mRNA/LNP technology to the development of innovative cancer therapies and treatments for autoimmune diseases. Concurrently, the company is actively leveraging AI technologies to enhance the design and development of neoantigens, targeting the broader biomedical frontier represented by preventive vaccines for infectious diseases and therapeutic vaccines for conditions such as cancer.